39828-37-0

Usage

Uses

Used in Pharmaceutical Industry:
Benzaldehyde, 2,4-dihydroxy-5-methylis used as an active pharmaceutical ingredient for the development of various medications. Its unique chemical structure allows it to interact with biological targets, offering potential therapeutic benefits in the treatment of certain diseases.
Used in Perfumery Industry:
Due to its sweet and almond-like aroma, Benzaldehyde, 2,4-dihydroxy-5-methylis used as a fragrance ingredient in the production of perfumes and scented products. Its pleasant scent adds depth and complexity to fragrance formulations.
Used in Flavoring Industry:
Benzaldehyde, 2,4-dihydroxy-5-methylis used as a flavoring agent in the food and beverage industry. Its characteristic almond-like flavor enhances the taste of various products, such as baked goods, confectionery, and beverages.
Used in Cosmetic and Personal Care Industry:
Leveraging its antioxidant and antimicrobial properties, Benzaldehyde, 2,4-dihydroxy-5-methylis used in the formulation of cosmetic and personal care products. It helps to protect products from oxidation and microbial contamination, ensuring their safety and efficacy.
Used in Chemical Synthesis:
Benzaldehyde, 2,4-dihydroxy-5-methylserves as a key intermediate in the synthesis of various organic compounds. Its unique functional groups make it a valuable building block for the development of new chemical entities with potential applications in various fields.
Used in Dye and Pigment Industry:
Benzaldehyde, 2,4-dihydroxy-5-methylis used in the manufacturing of dyes, pigments, and photographic chemicals. Its ability to form stable color complexes makes it suitable for use in the production of high-quality dyes and pigments for various applications, including textiles, plastics, and printing inks.

Upstream product

• 74-90-8 hydrogen cyanide 
• 496-73-1 4-methyl resorcinol 
• 68-12-2 N,N-dimethyl-formamide 
• 4885-02-3 Dichloromethyl methyl ether 
• 95-01-2 2,4-Dihydroxybenzaldehyde 

Downstream Products

• 615-89-4 2,4-dimethyl-5-hydroxyphenol 
• 855362-17-3 4-(benzyloxy)-2-hydroxy-5-methylbenzaldehyde 
• 35499-81-1 7-hydroxy-6-methyl-2-phenyl-chromenylium; chloride 
• 84422-52-6 2-hydroxy-4-methoxy-5-methylbenzaldehyde 
• 1174504-48-3 2,4-diacetoxy-5-methylbenzaldehyde 

Relevant academic research and scientific papers

Total synthesis of (±) mutisianthol and (±) epi-mutisianthol via intramolecular oxidative Heck cyclization approach Dedicated to the late Professor M. G. Kulkarni, Department of Chemistry, SPPU, Pune for his pioneering work in the field of Wittig olefinat

A simple and straight forward synthesis of (±) mutisianthol and its epimer is described. Implementation of 4-pentenal derivative for palladium catalyzed intramolecular 5-endo-trig Heck cyclization is effective. Other key steps involved are Wittig olefinat

Anti-AIDS agents 33.1 Synthesis and anti-HIV activity of mono-methyl substituted 3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogues

Four isomeric methyl substituted DCK analogues (2-5) were asymmetrically synthesized from different starting materials. 3-Methyl, 4-methyl, and 5- methyl-3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (2 -4) all were extremely potent against HIV-1 replication in H9 lymphocyte cells with EC50 and therapeutic index values of -7 μM and >3.72 x 108, respectively, which are much better than those of DCK and AZT in this assay.

HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR

The disclosure describes pyridinone-containing inhibitors of PD-L1, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds, and their use in the treatment of infectious diseases and cancer. Formula (I).

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS

Therapeutic combinations of hepatitis B virus (HBV) vaccines and PD-L1 inhibitors are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the dis

UREA COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF

The present invention relates to a urea compound and a preparation method and an application thereof. The structure of the present compound is represented by formula (I), the definition of each variable in the formula being as described in the description. The compound can block interaction between the PD-1/PD-L1 signalling pathways. The compound of the present invention can be used for treating or preventing diseases related to the signalling pathways, such as cancer, autoimmune disease, chronic infectious disease, and other diseases.

Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects

Heat shock protein 90 (Hsp90) is a chaperone under investigation for the treatment of cancer and neurodegenerative diseases. Neuroprotective Hsp90 C-terminal inhibitors derived from novobiocin (novologues) include KU-32 and KU-596. These novologues modulate molecular chaperones and result in an induction of Heat Shock Protein 70 (Hsp70). “Noviomimetics” replace the synthetically complex noviose sugar with a simple cyclohexyl moiety to maintain biological efficacy as compared to novologues KU-596 and KU-32. In this study, we further explore the development of noviomimetics and evaluate their efficacy using a luciferase refolding assay, immunoblot analysis, a c-jun assay, and an assay measuring mitochondrial bioenergetics. These new noviomimetics were designed and synthesized and found to induce Hsp70 and improve biological activity. Noviomimetics 39e and 40a were found to induce Hsp70 and exhibit promising effects in cellular assays.

Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer

Heat Shock Protein 90 (Hsp90) is a molecular chaperone under clinical investigation for the treatment of neurodegenerative diseases and cancer. Neuroprotective Hsp90 C-terminal inhibitors (novologues) contain a biaryl ring system, and include KU-596, which was modified and investigated for potential anti-cancer activity. Incorporation of a benzamide group onto the biaryl novologues in lieu of the acetamide yielded compounds that manifest anti-cancer activity. Further exploration of the central phenyl ring led to compounds with enhanced anti-proliferative activity. The design, synthesis, and evaluation of these new analogs against breast and prostate cancer cell lines is reported herein, where it was found that 8b and 10 manifest potent anti-proliferative activity and a robust degradation of Hsp90 client-dependent proteins.

1 -HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS

Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. The claimed compounds are described by the following Markush formula:A typical example for a compound according to above formula is: A typical example for a compound according to above formula is:

Anti-AIDS agents. 37. Synthesis and structure-activity relationships of (3'R,4'R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents

To explore the structural requirements of (+)-cis-khellactone derivatives as novel anti-HIV agents, 24 monosubstituted 3',4'-di-O-(S)- camphanoyl-(+)-cis-khellactone (DCK) derivatives were synthesized asymmetrically. These compounds included 4 isomeric monomethoxy analogues (3- 6), 4 isomeric monomethyl analogues (7-10), 4 4-alkyl/aryl-substituted analogues (11-14), and 12 4-methyl-(+)-cis-khellactone derivatives (15-26) with varying 3',4'-substituents. These (+)-cis-khellactone derivatives were screened against HIV-1 replication in acutely infected H9 lymphocytes. The results demonstrated that the (3'R,4'R)-(+)-cis-khellactone skeleton, two (S)-(-)-camphanoyl groups at the 3'- and 4'-positions, and a methyl group on the coumarin ring, except at the 6-position, were optimal structural moieties for anti-HIV activity. 3-Methyl- (7), 4-methyl- (8), and 5-methyl- (9) 3',4'- di-O-(S)-camphanoyl-(3'R,4'R)-(+)-cis-khellactone showed EC50 and therapeutic index values of -5 μM and >2.15 x 106, respectively, in H9 lymphocytes, which are much better than those of DCK and AZT in the same assay. Furthermore, 8 and 9 also showed potent inhibitory activity against HIV-1 replication in the CEM-SS cell line, and most monosubstituted DCK analogues were less toxic than DCK in both assays.